About Psoriasis Cure Now

Psoriasis Cure Now (PCN) launched in 2005 with a mission to increase research funding for psoriasis and psoriatic arthritis, to educate opinion leaders and the general public about the seriousness of psoriatic disease, and to inspire and support patients and their loved ones to live their best lives despite psoriasis. Founded and run by a psoriasis patient, Psoriasis Cure Now has been aided by the hard work and financial support of hundreds of volunteers across the United States. We are a 501(c)(3) nonprofit organization.

Focused primarily on those with moderate to severe psoriasis and/or psoriatic arthritis, PCN leverages its ability to target, nimbly, areas where the psoriasis community has unmet needs. Our scrappy, unconventional vision of patient advocacy makes us willing to shake up the status quo when the status quo is not adequately serving psoriasis patients. [Learn more about our story.]

Prior to launching Psoriasis Cure Now, its founder and president, Michael Paranzino, worked at the intersection of policy, politics, and communications; as Chief of Staff and Legislative Director to a Member of Congress, as a lobbyist for the US solar energy industry, and as a communications consultant and policy advocate. He has also practiced law; worked on political campaigns; and been interviewed hundreds of times for print, radio and television. He holds degrees from Yale University and the NYU School of Law. Five members of his extended family also have psoriasis, giving him, as he puts it, “plenty of skin in the game” – and the motivation to seek swift progress for the psoriasis community. Reach him directly at: michaelp@psoriasiscurenow.org.

If you would like to assist us, be it once a year or more frequently, we would love your help. Sign up on our Volunteer page and we will find a way to leverage your talents and passion to advance the mission we share.

Volunteer with Us

The Latest Psoriasis News

Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis
Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis

AbbVie, the North Chicago company behind the longtime blockbuster biologic Humira (adalimumab) and the new biologic Skyrizi (risankizumab-rzaa), has asked the U.S. Food and Drug Administration (FDA) and its European counterpart to approve its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for psoriatic arthritis. Rinvoq is a JAK inhibitor administered as Continue Reading…

Our new “Psoriasis Journey” campaign is rolling out
Our new “Psoriasis Journey” campaign is rolling out

Our new Psoriasis Journey campaign is rolling out now to prep for for an official June 8, 2020 launch. On that date, our volunteer patient with severe psoriasis is going to begin one of the cutting-edge psoriasis treatments we’ve been hearing so much about. You can follow along with his Continue Reading…

Want to try an experimental psoriasis treatment for your skin or scalp?
Want to try an experimental psoriasis treatment for your skin or scalp?

Before a doctor can prescribe a treatment, it goes through years of research and testing, including multiple rounds of clinical trials, using volunteer patients to test a potential treatment’s safety and effectiveness. The clinical trials are developed in consultation with government regulators (here, the US Food and Drug Administration, or Continue Reading…